<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094882</url>
  </required_header>
  <id_info>
    <org_study_id>ALMPILN</org_study_id>
    <nct_id>NCT05094882</nct_id>
  </id_info>
  <brief_title>Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC</brief_title>
  <acronym>ALMPILN</acronym>
  <official_title>Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in Non-small Cell Lung Cancer: a Multi-center, Prospective Observational Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes (Group 11-13) in&#xD;
      Non-small Cell Lung Cancer: a Multi-center, Prospective observational Clinical Trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients would be evaluated whether meet the criteria as clinical stage T1 non-small Cell&#xD;
      Lung Cancer. Then, he/she would receive lobectomy. Finally, the detailed anatomical location&#xD;
      of group 11-13 would be recorded immediately after surgery and their metastasis pattern would&#xD;
      be explored in the follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>metastasis rate of group 11-13 LN</measure>
    <time_frame>one month after surgery</time_frame>
    <description>metastasis rate of intrapulmonary lymph nodes (group 11-13 LN) in non-small cell lung cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>detailed anatomical location</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>number of group 11-13 intrapulmonary lymph nodes in Non-small cell lung cancer and their detailed anatomical location</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>RUL</arm_group_label>
    <description>patients who recieved the resection of right upper lobe (RUL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RML</arm_group_label>
    <description>patients who recieved the resection of right middle lobe ()</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLL</arm_group_label>
    <description>patients who recieved the resection of right lower lobe (RML)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LUL</arm_group_label>
    <description>patients who recieved the resection of left upper lobe (LUL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LLL</arm_group_label>
    <description>patients who recieved the resection of left lower lobe (LLL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pulmonary lobectomy</intervention_name>
    <description>resection of lung lobe</description>
    <arm_group_label>LLL</arm_group_label>
    <arm_group_label>LUL</arm_group_label>
    <arm_group_label>RLL</arm_group_label>
    <arm_group_label>RML</arm_group_label>
    <arm_group_label>RUL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage T1 peripheral non-small cell lung cancer (NSCLC) undergoing radical&#xD;
        lobectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Preoperative examination showed patients with clinical T1 peripheral non-small cell&#xD;
             lung cancer (NSCLC);&#xD;
&#xD;
          2. The lesion is located in a single lung segment or between two adjacent lung segments;&#xD;
&#xD;
          3. Perform radical lobectomy;&#xD;
&#xD;
          4. The preoperative examination did not reveal unresectable lymph nodes;&#xD;
&#xD;
          5. Have not received any other tumor-related treatments (including chemotherapy,&#xD;
             radiotherapy, targeted therapy, immunotherapy, etc.) before surgery;&#xD;
&#xD;
          6. No malignant tumor history;&#xD;
&#xD;
          7. No contraindications to surgery (ECOG score 0-1 points);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pathology revealed patients with non-T1 stage non-small cell lung cancer (NSCLC);&#xD;
&#xD;
          2. Radical lobectomy is not performed;&#xD;
&#xD;
          3. Acception of any anti-tumor treatment before surgery (excluding Chinese medicine&#xD;
             treatment);&#xD;
&#xD;
          4. Refused to enter the group or asked to leave the group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Affiliated Shanghai Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hong hu</last_name>
    <phone>86-13512102066</phone>
    <email>huhong0997@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Hu</last_name>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Haiquan Chen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Intrapulmonary Lymph Nodes</keyword>
  <keyword>Anatomical Location</keyword>
  <keyword>Metastasis Pattern</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study Protocol, Inform Consent Form, Clinical Study Report would be shared every 3 months after the study begin.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>every 3 months after the study begin.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

